Avalo Therapeutics (AVTX) Amortizatization of Intangibles (2017 - 2026)
Avalo Therapeutics' (AVTX) quarterly Amortizatization of Intangibles came in at $106000.0 in Q1 2026, down 46.19% on a QoQ basis from $197000.0 in Q4 2025.
Powered by 
Analysis
Avalo Therapeutics (AVTX) Amortizatization of Intangibles (2017 - 2026) Analysis & Trends
Avalo Therapeutics (AVTX) has 8 years of Amortizatization of Intangibles data on file, last reported at $106000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles changed N/A year-over-year to $106000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $796000.0 (changed N/A YoY) and the FY2025 annual result came in at $690000.0, changed N/A from the prior year.
- Amortizatization of Intangibles retreated to $106000.0 in Q1 2026, from $197000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $900000.0 in Q3 2023 to a low of $106000.0 in Q1 2026.
- A 4-year average of $344000.0 and a median of $349000.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- The widest YoY moves for Amortizatization of Intangibles: up 223.08% in 2022, down 0.0% in 2022.
- Tracing AVTX's Amortizatization of Intangibles over 4 years: stood at $349000.0 in 2022, then soared by 157.88% to $900000.0 in 2023, then tumbled by 78.11% to $197000.0 in 2025, then slumped by 46.19% to $106000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $106000.0 (Q1 2026), $197000.0 (Q4 2025), and $347000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Avalo Therapeutics | 843.26 Mn | 843.26 Mn | - | 418,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 418,000.00 |
| Mar 31, 2026 | 106,000.00 |
| Dec 31, 2025 | 197,000.00 |
| Sep 30, 2025 | 347,000.00 |
| Jun 30, 2025 | 146,000.00 |
| Sep 30, 2023 | 900,000.00 |
| Jun 30, 2023 | 349,000.00 |
| Mar 31, 2023 | 350,000.00 |
| Dec 31, 2022 | 349,000.00 |
| Sep 30, 2022 | 354,000.00 |
| Jun 30, 2022 | 336,000.00 |
| Mar 31, 2022 | 350,000.00 |
| Dec 31, 2021 | 349,000.00 |
| Sep 30, 2021 | 341,000.00 |
| Jun 30, 2021 | 104,000.00 |
| Dec 31, 2019 | -1.00 |
| Sep 30, 2019 | 67,032.00 |
| Jun 30, 2019 | 17,637.00 |
| Mar 31, 2019 | 22,603.00 |
| Dec 31, 2018 | 38,154.00 |